Clinical Trial Update: Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK) [Phase 1]

View source ↗

Summary

Phase I pediatric trial of LDK378 (alectinib) in ALK-activated tumors; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alk-activated Tumors

Drugs mentioned

• LDK378 (Alectinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: ALK-activated Tumors | Phase 1 | Status: COMPLETED | Results posted: 2020-06-09